Browse

High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy

Cited 35 time in Web of Science Cited 40 time in Scopus
Authors
Lee, Kyung-Hun; Lee, Se-Hoon; Kim, Dong-Wan; Kang, Won Jun; Chung, June-Key; Im, Seock-Ah; Kim, Tae-You; Kim, Young Whan; Bang, Yung-Jue; Heo, Dae Seog
Issue Date
2006-07
Publisher
American Association for Cancer Research
Citation
Clinical Cancer Research, Vol.12 No.14, pp.4232-4236
Keywords
AgedAntineoplastic Combined Chemotherapy Protocols/*therapeutic useCarcinoma, Non-Small-Cell Lung/*diagnosis/*radionuclide imagingCisplatin/*administration & dosageFemaleFluorodeoxyglucose F18/*pharmacokineticsHumansLung Neoplasms/*diagnosis/*radionuclide imagingMaleMiddle AgedPositron-Emission Tomography/*methodsRadiopharmaceuticals/*diagnostic useRetrospective StudiesTime FactorsTreatment Outcome
Abstract
Purpose: To evaluate response and survival for platinum-based combination chemotherapy in chemonaive patients with non - small cell lung cancer (NSCLC) according to pretreatment standardized uptake values (SUV) by fluorodeoxyglucose positron emission tomography. Experimental Design: Patients with advanced NSCLC who had not previously received chemotherapy were eligible. Response rates and survivals were analyzed according to maximal SUVs [low (<= 7.5) versus high (>7.5), where 7.5 was the median value] before the first cycle of chemotherapy. Results: Eighty-five consecutive patients were included in the retrospective study. Patients with high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs versus 61.0% for high SUVs; P = 0.013). Other factors, including sex, age, histology, performance status, number of involved organs, regimens used, and disease stage, did not affect response. However, high SUVs were related with a shorter response duration (279 days for low SUVs versus 141 days for high SUVs; P = 0.003) and time to progression (282 days for low SUVs versus 169 days for high SUVs; P = 0.015). Overall survival was unaffected by maximal SUVs (623 days for low SUVs versus 464 days for high SUVs; P = 0.431). Conclusions: Patients having NSCLC with high maximal SUVs showed a better response to platinum-based combination chemotherapy but had a shorter time to progression. Tumor glucose metabolism, as determined by SUVs on fluorodeoxyglucose positron emission tomography, was found to discriminate NSCLC subsets with different clinical and biological features.
ISSN
1078-0432
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16857796

http://hdl.handle.net/10371/28463
DOI
https://doi.org/10.1158/1078-0432.CCR-05-2710
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse